Cell Therapy Analytics
& Quality Control
Cell therapy QC is not protein analytics adapted for cells. DES Pharma develops and validates the flow cytometry panels, potency assays,
vector copy number methods, and lot release strategies that reflect what a living cell product actually requires and what
CBER/OTAT reviewers expect to see.
Analytical DevelopmentAnalytics Designed Around Cell Therapy CQAs
The critical quality attributes of a cell therapy product are not static, and they cannot be assayed using methods borrowed from protein analytics. Viability, immunophenotype, CAR expression, memory subset distribution, transduction efficiency, vector copy number, potency, and sterility are all measured on living cells, with time constraints, cryopreservation variables, and platform-specific reagent considerations that require purpose-built analytical strategies.
DES Pharma develops cell therapy analytical programs from the ground up, establishing an Analytical Target Profile (ATP) aligned to the Target Product Profile (TPP) before a single method is designed. Lot release for cryopreserved living products requires a strategy, not just a checklist, including rapid release approaches for autologous programs where product shelf life is limited.
Critical Quality AttributesCell Therapy CQA Framework
& Analytical Methods
The CQA panel for a cell therapy product reflects the biology of the product and the risk profile of the target patient population. DES Pharma helps programs define, prioritize, and measure the attributes that matter most.
| Critical Quality Attribute | Category | Primary Analytical Method(s) | Stage Notes |
|---|---|---|---|
| Cell Viability | Viability | 7-AAD / DAPI exclusion by flow cytometry; trypan blue (process monitoring) | Pre- and post-cryopreservation; critical for release specification |
| Immunophenotype (T-cell subset) | Identity | Multicolor flow cytometry (CD3, CD4, CD8, CD45RA, CCR7, CD27, CD62L) | Memory subset profiling increasingly expected at Phase 3 and BLA |
| CD4/CD8 Ratio | Identity | Flow cytometry (CD3/CD4/CD8 co-stain) | Composition CQA correlated with clinical efficacy; BLA specification with clinical outcome justification |
| CAR Expression | Identity | Anti-idiotype antibody or protein L staining by flow cytometry | CAR+ % is a release criterion; must track with transduction efficiency |
| Transduction Efficiency | Identity | Flow cytometry for CAR surface expression; correlated with VCN | Process monitoring; informs MOI and process parameter optimization |
| Vector Copy Number (VCN) | Identity | ddPCR (preferred for precision); qPCR with validated reference standards | Safety-relevant; FDA expects VCN data with CBER/OTAT IND submissions |
| Karyotyping & Insertional Oncogenesis | Safety | G-banding karyotype; insertional site analysis (LAM-PCR) | Required for allogeneic programs with prolonged expansion; genotoxicity risk assessment |
| Potency | Potency | Cytotoxicity assay (co-culture); cytokine release (IFN-γ, IL-2 ELISA/MSD); xCELLigence RTCA | Surrogate assay in Phase 1; mechanism-based validated assay required at BLA |
| RCL / RCR Testing | Safety | TZM-bl indicator cell co-culture; p24 ELISA (RCL); RT-PCR (RCR) per FDA | Required for lentiviral and retroviral transduced products; ICH Q5A viral safety alignment |
| Sterility | Safety | Compendial sterility (USP <71>); validated rapid NAT-based methods | Rapid methods critical for autologous programs; concurrent release procedures |
| Mycoplasma | Safety | NAT-based PCR; culture method as compendial reference | NAT enables faster results; required for lot release |
| Endotoxin (LAL) | Safety | Kinetic turbidimetric or chromogenic LAL; recombinant Factor C (rFC) | Release criterion; critical for IV-administered products |
| Residual Beads | Purity | Flow cytometry bead count; hemacytometer-based counting | Applicable to bead-based activation platforms; FDA expects depletion data |
| Residual DMSO | Purity | HPLC or NMR; enzymatic colorimetric assay | Cryopreserved products: specification based on maximum patient dose |
| Identity (Donor/Patient) | Identity | STR profiling; HLA typing for allogeneic; chain of identity documentation | 21 CFR Part 1271 requirement; critical for autologous COI verification |
Analytical Development ServicesMethod Development &
Validation for Living Cell Products
Every analytical method for cell therapy lot release must account for the specific challenges of a cryopreserved, living biological product, with time constraints, donor variability, and platform-specific reagent considerations that require purpose-built strategies.
Identity & Phenotyping
Flow Cytometric Immunophenotyping
Multicolor panel design and optimization for T-cell subset analysis, CAR surface expression, memory phenotype profiling (Tscm, Tcm, Tem), and CD4/CD8 ratio characterization. The panel is appropriate to the CDMO instrument platform with reagent lot bridging procedures.
Genetic Modification
Vector Copy Number (ddPCR / qPCR)
VCN assay development by droplet digital PCR for high-precision quantitation across the CAR-transgene integration site. Assay qualification and validation aligned with CBER/OTAT expectations. Method transfer to CDMO QC laboratory with inter-laboratory concordance data.
Potency
Cytotoxicity & Cytokine Release Assays
CAR-T cytotoxicity assay development using target antigen-expressing cell lines, E:T ratio optimization, and endpoint selection, including LDH release, annexin-V, and xCELLigence RTCA for impedance-based continuous monitoring. IFN-γ, IL-2, and TNF-α ELISA or MSD multiplex as surrogate potency attributes.
Safety Testing
RCL / RCR Detection
Replication-competent lentivirus (RCL) testing using TZM-bl indicator cell co-culture assays and p24 ELISA confirmation. RCR detection by RT-PCR per FDA-specified methods. ICH Q5A-aligned viral safety evaluation packages for CBER/OTAT review.
Viability & Function
Post-Thaw Characterization
Post-thaw viability (7-AAD, DAPI, trypan blue), recovery characterization, functionality retention studies, and cryopreserved product stability study design. Bridging pre- and post-cryopreservation analytical results for lot release and comparability packages.
Rapid Release
Stage-Appropriate Lot Release Strategy
Release panel design for autologous programs with compressed timelines. Rapid sterility (NAT-based), rapid mycoplasma, concurrent release approaches, and provisional release with defined hold/release decision trees. ICH Q14 and Q2(R2) method lifecycle management.
Analytical CapabilitiesTechnical Depth in Cell Therapy Analytics
The analytical challenges of cell therapy are unique. Living products on compressed timelines, cryopreservation variables that affect every assay, and a regulatory framework that is still evolving require an analytical partner with real operational depth.
Rapid & Provisional Release
For autologous CAR-T programs, lot release is time-constrained by patient scheduling. We design rapid release systems (validated rapid sterility, NAT-based mycoplasma, and provisional release with confirmatory procedures) that meet CBER requirements without compromising the patient timeline.
Potency Assay Strategy
Surrogate assays (cytokine release, activation markers) in early stages, mechanistic cytotoxicity assays during Phase 2, and a validated mechanism-of-action-based assay in the BLA, with clear bridging data across the development program aligned to the 2011 CBER Potency Guidance.
Method Transfer to CDMO
Analytical methods developed in-house must be transferable to your CDMO without losing performance. We design transfer protocols, execute inter-laboratory comparability studies, and generate qualification data that supports IND amendments and BLA submissions following CDMO changes.
CBER/OTAT Submission Readiness
Method qualification and validation reports, lot release specifications, and stability study designs that reflect current CBER/OTAT review standards and ICH Q14 requirements for analytical procedure development and lifecycle management.
Lot Release StrategyStage-Appropriate
Release Panel Design
Cell therapy lot release specifications evolve as the program progresses. We help programs build release panels that are scientifically defensible at each clinical stage and commercially practical at launch.
| Development Stage | Release Testing Priority | Key Considerations |
|---|---|---|
| Phase 1 (IND) | Viability, sterility, mycoplasma, endotoxin, identity (COI), CAR expression, VCN | Rapid / provisional release with concurrent testing and confirmatory hold samples; real-time sterility incubation with defined hold/release decision tree |
| Phase 2 | Above plus potency (surrogate or cytotoxicity), residual beads, residual DMSO, RCL/RCR | Potency assay required by Phase 2 per FDA guidance; method qualification expected; stability data from Phase 1 cryopreserved product informs shelf life specification |
| Phase 3 / PPQ | Full validated release panel per commercial BLA specification; all methods validated per ICH Q2(R2) | Release specifications set from Phase 1–2 manufacturing data; potency specification justified with clinical or mechanistic correlation; VCN specification with safety justification |
| Commercial / BLA | As above; rapid sterility fully validated; stability-indicating methods across shelf life; ICH Q14 lifecycle management | CBER expects method validation data in BLA CTD Module 3; post-approval stability commitments and ongoing method performance monitoring per ICH Q14 |
Get Started Ready to Build a Cell Therapy Analytical Program That Holds Up to CBER/OTAT Scrutiny?
From flow panel design through potency validation and rapid lot release strategy, DES Pharma brings the analytical depth your program needs.